drugset / Trial / NCT00372528
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to continue to study the long term safety of pregabalin administered as adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with refractory partial seizures.
Timeline
- Start
- 2007-03
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 150 mg | — |
| Subject | Pregabalin | Small molecule | 600 mg | — |